AtriCure

AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip® LAA Exclusion System, the most widely placed left atrial appendage device worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.
Type
Public
HQ
Mason, US
Employees
430 (est)
AtriCure is headquartered in Mason, US

Key People at AtriCure

Michael H. Carrel

Michael H. Carrel

President & CEO
Thomas Hancock

Thomas Hancock

Investor
M. Andrew Wade

M. Andrew Wade

VP & CFO
Lee Wrubel

Lee Wrubel

Associate
Mike Hooven

Mike Hooven

Founder &Director

AtriCure Locations

Mason, US
Minnetonka, US
San Ramon, US
Amsterdam, NL
Minneapolis, US
Cincinnati, US
Morrisville, US
Mobile, US
Beijing, CN
Portland, US
Boston, US
Louisville, US
Indianapolis, US
West Chester, US
Los Angeles, US

AtriCure Metrics

AtriCure Summary

Market capitalization

$612 M

Closing share price

$18.6
AtriCure's latest market capitalization is $612 M.

AtriCure Market Value History

AtriCure Online Presence

AtriCure Company Life

You may also be interested in